Glymphatic Pathway in Brain Imaging

Sponsor
Paracelsus Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05035251
Collaborator
(none)
60
1
48
1.3

Study Details

Study Description

Brief Summary

To investigate the pathways of Gadolinium-based contrast agent (GBCA) in different brain compartments and evaluate correlations of GBCA enhancement with specific diseases.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    To investigate the contrast enhancement in different brain compartments. Until recently, it had been assumed that Gadolinium-based contrast agents do not cross the blood-brain barrier, but delayed imaging revealed signal increase in a number of compartments in the CSF (the perilymph of the inner ear, the internal auditory canal, the Meckel's cave, the suprasellar cistern, the ambient cistern and anterior eye compartment). These findings suggested, that Gadolinium-based contrast agents (GBCA) penetrate into the CSF through the choroid plexus and the aqueous chamber of the eye. MRI has provided the evidence of presence of meningeal lymphatic vessels in human and non-human primates for central nervous system waste clearance. It has been demonstrated that heavily T2-weighted fluid-attenuated inversion recovery (hT2w-FLAIR) MRI detects even very low concentrations of GBCA in the CSF.

    The aim of our study is to find specific enhancement patterns in various cerebral compartments in correlation with specific diseases and procedures such as radiation, surgery and drug application in delayed gadolinium imaging. Only patients with a clinical indication for GBCA will be included in this prospective study. Before enrollment, each patient will have provided written informed consent of participation and publication prior to inclusion to the observational study. The scan will be performed as baseline before intravenous contrast administration of a single dose of gadoteric acid 20 minutes and 120 minutes after contrast administration. Whole-brain image stacks will be analyzed on patient basis. Regions of interest for signal intensity measurements will be drawn in various cerebral fluid spaces, the size of the region of interest will depend on the target structure. The following structures should be measured: lateral and central aqueous chamber and vitreous body of the eye, distal optic nerve sheath, Meckel's cave, lateral ventricles and basal cisterns.

    Data will be expressed as mean values +/- one-fold standard deviation (SD). The normality of data distribution will be assessed using Levene's test. Data showing a Gaussian distribution will be evaluated by an analysis of variances (ANOVA) with a post-hoc analysis. Estimated sample size is around 30 patients in the control and the experimental group. Cases with missing or unavailable data will be excluded.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    60 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Glymphatic Pathway in Brain Imaging: Evaluation of MRI Findings
    Actual Study Start Date :
    Jul 1, 2020
    Anticipated Primary Completion Date :
    Nov 11, 2023
    Anticipated Study Completion Date :
    Jul 1, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    experimental

    patients with a condition

    control

    patients without condition

    Outcome Measures

    Primary Outcome Measures

    1. Change of Signal-Intensity (SI)-Measurements with ROI in 3 specific MRI Scans [Baseline (nativ scan), 20 minutes and 120 minutes after contrast media application]

      Regions of interest for signal intensity measurements will be drawn in various cerebral fluid spaces, the size of the region of interest will depend on the target structure. Following structures will be measured: lateral and central aqueous chamber and vitreous body of the eye, distal optic nerve sheath, Meckel's cave, lateral ventricles and basal cisterns.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Only patients with a clinical indication for GBCA

    • Written informed consent

    • No allergies to GBCA

    Exclusion Criteria:
    • Contraindications for MRI

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Institute of Radiology and Nuclear Medicine Nuremberg Bavaria Germany 90419

    Sponsors and Collaborators

    • Paracelsus Medical University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Dr. Panagiota Manava, Senior physician, Institute of Radiology and Nuclear Medicine, Klinikum Nuernberg, Paracelsus Medical University
    ClinicalTrials.gov Identifier:
    NCT05035251
    Other Study ID Numbers:
    • GP_2021_KNN
    First Posted:
    Sep 5, 2021
    Last Update Posted:
    Sep 5, 2021
    Last Verified:
    Aug 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Dr. Panagiota Manava, Senior physician, Institute of Radiology and Nuclear Medicine, Klinikum Nuernberg, Paracelsus Medical University

    Study Results

    No Results Posted as of Sep 5, 2021